This early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…
Phase: PHASE1, PHASE2 • Sponsor: Sotio Biotech Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC